Analyst Price Targets — RPRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 21, 2026 11:14 am | Ashwani Verma | UBS | $57.00 | $49.30 | TheFly | Royalty Pharma price target raised to $57 from $51 at UBS |
| April 10, 2026 12:56 pm | Terence Flynn | Morgan Stanley | $63.00 | $47.98 | TheFly | Royalty Pharma price target raised to $63 from $61 at Morgan Stanley |
| February 27, 2026 6:43 pm | — | Seaport Global | $50.00 | $46.21 | StreetInsider | Royalty Pharma (RPRX) PT Raised to $50 at TD Cowen |
| February 12, 2026 1:14 pm | Terence Flynn | Morgan Stanley | $61.00 | $44.71 | TheFly | Royalty Pharma price target raised to $61 from $56 at Morgan Stanley |
| January 30, 2026 9:40 am | Ashwani Verma | UBS | $49.00 | $40.86 | TheFly | Royalty Pharma upgraded to Buy from Neutral at UBS |
| December 11, 2025 3:12 pm | — | Leerink Partners | $45.00 | $38.22 | StreetInsider | Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' |
| September 30, 2025 9:10 am | — | Goldman Sachs | $42.00 | $35.25 | TheFly | Royalty Pharma initiated with a Buy at Goldman Sachs |
| July 10, 2025 12:34 pm | Terence Flynn | Morgan Stanley | $54.00 | $36.14 | TheFly | Royalty Pharma price target raised to $54 from $51 at Morgan Stanley |
| September 4, 2024 7:44 am | Chris Shibutani | Goldman Sachs | $51.00 | $29.16 | StreetInsider | Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX) |
| July 11, 2024 8:15 am | Terence Flynn | Morgan Stanley | $51.00 | $25.73 | TheFly | Royalty Pharma price target raised to $51 from $48 at Morgan Stanley |
Latest News for RPRX
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RPRX.
U.S. House Trading
No House trades found for RPRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.